Latest News on LENZ

Financial News Based On Company

Want to find fair value of LENZ?

LENZ Therapeutics, Inc. ( LENZ ) Reports Q3 Loss, Beats Revenue Estimates

https://www.zacks.com/stock/news/2785553/lenz-therapeutics-inc-lenz-reports-q3-loss-beats-revenue-estimates

LENZ Therapeutics, Inc. (LENZ) delivered earnings and revenue surprises of +11.94% and +92.31%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

LENZ Therapeutics, Inc. ( LENZ ) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

https://www.zacks.com/stock/news/2781495/lenz-therapeutics-inc-lenz-may-find-a-bottom-soon-heres-why-you-should-buy-the-stock-now

After losing some value lately, a hammer chart pattern has been formed for LENZ Therapeutics, Inc. (LENZ), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Artelo Biosciences Names Veteran Life Sciences Executive Mark Spring, CPA, as Chief Financial Officer - Artelo Biosciences ( NASDAQ:ARTL )

https://www.benzinga.com/pressreleases/25/10/g48429770/artelo-biosciences-names-veteran-life-sciences-executive-mark-spring-cpa-as-chief-financial-office

SOLANA BEACH, Calif., Oct. 27, 2025 ( GLOBE NEWSWIRE ) -- Artelo Biosciences, Inc. ( NASDAQ:ARTL ) , a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological, or neurological conditions, today ...

LENZ Therapeutics, Inc. ( LENZ ) Upgraded to Buy: What Does It Mean for the Stock?

https://www.zacks.com/stock/news/2774399/lenz-therapeutics-inc-lenz-upgraded-to-buy-what-does-it-mean-for-the-stock

LENZ Therapeutics, Inc. (LENZ) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Gene Therapy for SCID Market is Expected to Reach at a US$ 2.0 Billion by 2034 | Fact.MR Report

https://www.benzinga.com/pressreleases/24/11/g41935864/gene-therapy-for-scid-market-is-expected-to-reach-at-a-us-2-0-billion-by-2034-fact-mr-report

Rockville, MD, Nov. 13, 2024 ( GLOBE NEWSWIRE ) -- According to Fact.MR, a market research and competitive intelligence provider, the global gene therapy for SCID market is projected to grow at a robust CAGR and could reach US$ 2.0 billion by 2034.

MaxCyte Signs Strategic Platform License with Kamau Therapeutics to Accelerate the Development of Cell Therapies for Genetic Diseases

https://www.globenewswire.com/news-release/2024/09/16/2946330/0/en/MaxCyte-Signs-Strategic-Platform-License-with-Kamau-Therapeutics-to-Accelerate-the-Development-of-Cell-Therapies-for-Genetic-Diseases.html

Kamau to use MaxCyte's Flow Electroporation® technology and ExPERT™ platform to support its homology-directed repair ( HDR ) novel gene correction technology Kamau to use MaxCyte's Flow Electroporation® technology and ExPERT™ platform to support its homology-directed repair ( HDR ) novel gene ...

MaxCyte Signs Strategic Platform License with Kamau Therapeutics to Accelerate the Development of Cell Therapies for Genetic Diseases - MaxCyte ( NASDAQ:MXCT )

https://www.benzinga.com/pressreleases/24/09/g40871379/maxcyte-signs-strategic-platform-license-with-kamau-therapeutics-to-accelerate-the-development-of-

ROCKVILLE, Md. and SOUTH SAN FRANCISCO, Calif., Sept. 15, 2024 ( GLOBE NEWSWIRE ) -- MaxCyte, Inc., MXCTMXCT ) ) , a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based ...

Blindness-Focused LENZ Therapeutics' Investigational Eye Drop Ready To Revolutionize Presbyopia Landscape, Analyst Says - LENZ Therapeutics ( NASDAQ:LENZ )

https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38190459/blindness-focused-lenz-therapeutics-investigational-eye-drop-ready-to-revolutionize

Last week, LENZ Therapeutics Inc LENZ released topline results from its Phase 3 CLARITY study of two investigational formulations of aceclidine, LNZ100 and LNZ101.

Manual One-Time Payment

Use this form to send a single payment (e.g., $5, $10, $15, etc.) for any agreed amount such as partial subscription catch-up, small adjustments, or one-off services.

Regular subscriptions are charged automatically through your plan. This form is only for extra one-time payments when requested.

Disclaimer

The Value-Trades website is intended for informational purposes only. The content provided on this website, including but not limited to recommendations, analysis, and opinions, should not be considered financial advice. Before making any investment decisions, whether buying or selling, based on information obtained from this website, it is imperative that you conduct your own thorough due diligence. This includes consulting with a qualified financial advisor, reviewing financial statements, and understanding the risks involved in any investment. The owner of this website shall not be held responsible for any financial losses incurred as a result of using the information provided herein. Investing in financial markets involves risk, and past performance is not indicative of future results. You are solely responsible for your investment decisions.